Serveur d'exploration sur les relations entre la France et l'Australie

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study

Identifieur interne : 006322 ( Main/Exploration ); précédent : 006321; suivant : 006323

Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study

Auteurs : Albert F. G. Leentjens [Pays-Bas] ; Kathy Dujardin [France] ; Laura Marsh [États-Unis] ; Pablo Martinez-Martin [Espagne] ; Irene H. Richard [États-Unis] ; Sergio E. Starkstein [Australie]

Source :

RBID : ISTEX:BAC9A14C486FC4DDDE842C685558E2300E5FB8FB

Descripteurs français

English descriptors

Abstract

Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross‐sectional study, 342 patients suffering from idiopathic PD underwent a research‐based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty‐four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono‐amino oxidase (MAO)‐B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD. © 2011 Movement Disorder Society

Url:
DOI: 10.1002/mds.23528


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study</title>
<author>
<name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
</author>
<author>
<name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
</author>
<author>
<name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
</author>
<author>
<name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
</author>
<author>
<name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
</author>
<author>
<name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:BAC9A14C486FC4DDDE842C685558E2300E5FB8FB</idno>
<date when="2011" year="2011">2011</date>
<idno type="doi">10.1002/mds.23528</idno>
<idno type="url">https://api.istex.fr/document/BAC9A14C486FC4DDDE842C685558E2300E5FB8FB/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002290</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002290</idno>
<idno type="wicri:Area/Istex/Curation">002290</idno>
<idno type="wicri:Area/Istex/Checkpoint">000741</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000741</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Leentjens A:symptomatology:and:markers</idno>
<idno type="wicri:Area/Main/Merge">006698</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:11-0211297</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001E14</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004126</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001638</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001638</idno>
<idno type="wicri:doubleKey">0885-3185:2011:Leentjens A:symptomatology:and:markers</idno>
<idno type="wicri:Area/Main/Merge">006A89</idno>
<idno type="wicri:Area/Main/Curation">006322</idno>
<idno type="wicri:Area/Main/Exploration">006322</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study
<ref type="note" target="#fn"></ref>
</title>
<author>
<name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Psychiatry, Maastricht University Medical Center, Maastricht</wicri:regionArea>
<wicri:noRegion>Maastricht</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Pays-Bas</country>
</affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Correspondence address: Department of Psychiatry, Maastricht University Medical Center, P.O. Box 5800, 6202 AZ Maastricht</wicri:regionArea>
<wicri:noRegion>6202 AZ Maastricht</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
<affiliation wicri:level="3">
<country xml:lang="fr">France</country>
<wicri:regionArea>Neurology and Movement Disorders Unit, Lille University Hospital, Lille</wicri:regionArea>
<placeName>
<region type="region">Hauts-de-France</region>
<region type="old region">Nord-Pas-de-Calais</region>
<settlement type="city">Lille</settlement>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<affiliation wicri:level="3">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Psychiatry and Neurology, Johns Hopkins University School of Medicine, Baltimore</wicri:regionArea>
<placeName>
<settlement type="city">Baltimore</settlement>
<region type="state">Maryland</region>
</placeName>
</affiliation>
<affiliation wicri:level="3">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Current Address: Mental Health Care Line, Michael E. DeBakey Veterans Administration Medical Center and Menninger Department of Psychiatry, Baylor College of Medicine, Houston</wicri:regionArea>
<placeName>
<settlement type="city">Houston</settlement>
<region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Area of Applied Epidemiology and CIBERNED, National Centre for Epidemiology, Carlos III Institute of Health, Madrid</wicri:regionArea>
<placeName>
<settlement type="city">Madrid</settlement>
<region nuts="2" type="region">Communauté de Madrid</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
<affiliation wicri:level="1">
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester</wicri:regionArea>
<wicri:noRegion>Rochester</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Psychiatry, University of Western Australia and Fremantle Hospital, Fremantle</wicri:regionArea>
<wicri:noRegion>Fremantle</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j" type="main">Movement Disorders</title>
<title level="j" type="alt">MOVEMENT DISORDERS</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint>
<biblScope unit="vol">26</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="484">484</biblScope>
<biblScope unit="page" to="492">492</biblScope>
<biblScope unit="page-count">9</biblScope>
<publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2011-02-15">2011-02-15</date>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Acute stress syndrome</term>
<term>Agoraphobia</term>
<term>Anxiety</term>
<term>Anxiety disorder</term>
<term>Anxiety disorders</term>
<term>Anxiety rating scales</term>
<term>Anxiety symptoms</term>
<term>Anxiety syndromes</term>
<term>Anxiety tension fear sleeplessness depression</term>
<term>Autonomic dysfunction</term>
<term>Beck</term>
<term>Beck anxiety inventory</term>
<term>Breathing fear</term>
<term>Clinical interview</term>
<term>Continuous variables</term>
<term>Cross sectional study</term>
<term>Depression</term>
<term>Depressive</term>
<term>Depressive symptoms</term>
<term>Diagnostic categories</term>
<term>Diagnostic groups</term>
<term>Different anxiety disorders</term>
<term>Disease duration</term>
<term>Disease rating scale</term>
<term>Disord</term>
<term>Disorder</term>
<term>Evaluation scale</term>
<term>Generalized anxiety disorder</term>
<term>Hamilton anxiety rating scale</term>
<term>Hamilton depression rating scale</term>
<term>Hars</term>
<term>Hars item scores</term>
<term>Hoehn yahr stage</term>
<term>Iadl</term>
<term>Independent variables</term>
<term>Indigestion face</term>
<term>Individual anxiety disorders</term>
<term>Individual anxiety syndromes</term>
<term>Individual item level</term>
<term>Individual items</term>
<term>Inhibitor</term>
<term>Instrumental activities</term>
<term>Inventory</term>
<term>Item scores</term>
<term>Lemeshow test</term>
<term>Lightheaded heart</term>
<term>Limited number</term>
<term>Logistic</term>
<term>Logistic model</term>
<term>Logistic regression</term>
<term>Logistic regression analysis</term>
<term>Maastricht university</term>
<term>Major depressive episode</term>
<term>Meeting criteria</term>
<term>Mini</term>
<term>Mini interview</term>
<term>Movement disorder society</term>
<term>Movement disorders</term>
<term>Multiple anxiety disorders</term>
<term>Multiple anxiety syndromes</term>
<term>Nervous system diseases</term>
<term>Neurol neurosurg psychiatr</term>
<term>Neuropsychiatry clin neurosci</term>
<term>Odds ratios</term>
<term>Other anxiety disorders</term>
<term>Panic disorder</term>
<term>Parkinson disease</term>
<term>Phobia</term>
<term>Pontone</term>
<term>Potential markers</term>
<term>Prevalence</term>
<term>Prevalence rates</term>
<term>Prevalent disorders</term>
<term>Previous history</term>
<term>Primary care</term>
<term>Psychometric properties</term>
<term>Questionable validity</term>
<term>Relevant anxiety</term>
<term>Relevant anxiety symptoms</term>
<term>Risk factors</term>
<term>Same analysis</term>
<term>Social phobia</term>
<term>Social phobia agoraphobia</term>
<term>Standard deviation</term>
<term>State examination</term>
<term>Stress syndrome</term>
<term>Study reports</term>
<term>Symptom</term>
<term>Symptomatology</term>
<term>Symptoms senses</term>
<term>Syndrome</term>
<term>Test statistic</term>
<term>Uctuations</term>
<term>Updrs</term>
<term>Updrs item</term>
<term>Validation study</term>
<term>Various anxiety disorders</term>
<term>Wilks lambda</term>
<term>Work group</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Angoisse anxiété</term>
<term>Echelle d'évaluation</term>
<term>Etat dépressif</term>
<term>Etude transversale</term>
<term>Inventaire</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Symptomatologie</term>
<term>Trouble anxieux</term>
</keywords>
<keywords scheme="Teeft" xml:lang="en">
<term>Acute stress syndrome</term>
<term>Agoraphobia</term>
<term>Anxiety</term>
<term>Anxiety disorder</term>
<term>Anxiety disorders</term>
<term>Anxiety rating scales</term>
<term>Anxiety symptoms</term>
<term>Anxiety syndromes</term>
<term>Anxiety tension fear sleeplessness depression</term>
<term>Autonomic dysfunction</term>
<term>Beck</term>
<term>Beck anxiety inventory</term>
<term>Breathing fear</term>
<term>Clinical interview</term>
<term>Continuous variables</term>
<term>Depressive</term>
<term>Depressive symptoms</term>
<term>Diagnostic categories</term>
<term>Diagnostic groups</term>
<term>Different anxiety disorders</term>
<term>Disease duration</term>
<term>Disease rating scale</term>
<term>Disord</term>
<term>Disorder</term>
<term>Generalized anxiety disorder</term>
<term>Hamilton anxiety rating scale</term>
<term>Hamilton depression rating scale</term>
<term>Hars</term>
<term>Hars item scores</term>
<term>Hoehn yahr stage</term>
<term>Iadl</term>
<term>Independent variables</term>
<term>Indigestion face</term>
<term>Individual anxiety disorders</term>
<term>Individual anxiety syndromes</term>
<term>Individual item level</term>
<term>Individual items</term>
<term>Inhibitor</term>
<term>Instrumental activities</term>
<term>Item scores</term>
<term>Lemeshow test</term>
<term>Lightheaded heart</term>
<term>Limited number</term>
<term>Logistic</term>
<term>Logistic model</term>
<term>Logistic regression</term>
<term>Logistic regression analysis</term>
<term>Maastricht university</term>
<term>Major depressive episode</term>
<term>Meeting criteria</term>
<term>Mini</term>
<term>Mini interview</term>
<term>Movement disorder society</term>
<term>Movement disorders</term>
<term>Multiple anxiety disorders</term>
<term>Multiple anxiety syndromes</term>
<term>Neurol neurosurg psychiatr</term>
<term>Neuropsychiatry clin neurosci</term>
<term>Odds ratios</term>
<term>Other anxiety disorders</term>
<term>Panic disorder</term>
<term>Phobia</term>
<term>Pontone</term>
<term>Potential markers</term>
<term>Prevalence</term>
<term>Prevalence rates</term>
<term>Prevalent disorders</term>
<term>Previous history</term>
<term>Primary care</term>
<term>Psychometric properties</term>
<term>Questionable validity</term>
<term>Relevant anxiety</term>
<term>Relevant anxiety symptoms</term>
<term>Risk factors</term>
<term>Same analysis</term>
<term>Social phobia</term>
<term>Social phobia agoraphobia</term>
<term>Standard deviation</term>
<term>State examination</term>
<term>Stress syndrome</term>
<term>Study reports</term>
<term>Symptom</term>
<term>Symptoms senses</term>
<term>Syndrome</term>
<term>Test statistic</term>
<term>Uctuations</term>
<term>Updrs</term>
<term>Updrs item</term>
<term>Validation study</term>
<term>Various anxiety disorders</term>
<term>Wilks lambda</term>
<term>Work group</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Anxiety is understudied in Parkinson's disease (PD), which is not justified by the prevalence and impact of anxiety disorders on quality of life in PD patients. In this cross‐sectional study, 342 patients suffering from idiopathic PD underwent a research‐based assessment including DSM IV criteria for anxiety disorders, the Hamilton anxiety rating scale (HARS) and the beck anxiety inventory (BAI). Thirty‐four percent (34%) of subjects met the DSM IV criteria for at least one anxiety disorder; 11.8% met criteria for multiple anxiety disorders; and 11.4% had clinically relevant anxiety symptoms without meeting the criteria for any specific anxiety disorder. Score profiles on the HARS and BAI differed significantly between the disorders, but these differences were associated with different scores on a limited number of items, and the respective symptom profiles were not readily interpretable. Female sex, the presence of motor fluctuations, as well as a previous history of an anxiety disorder were markers for anxiety disorders. The use of a mono‐amino oxidase (MAO)‐B inhibitor was associated with a reduced prevalence of anxiety disorders. Research into anxiety in PD is hampered by the questionable validity of DSM IV defined anxiety disorders in this population. A first focus for research should therefore be the identification of clinically useful anxiety presentations and their validation in PD. © 2011 Movement Disorder Society</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Australie</li>
<li>Espagne</li>
<li>France</li>
<li>Pays-Bas</li>
<li>États-Unis</li>
</country>
<region>
<li>Communauté de Madrid</li>
<li>Hauts-de-France</li>
<li>Maryland</li>
<li>Nord-Pas-de-Calais</li>
<li>Texas</li>
</region>
<settlement>
<li>Baltimore</li>
<li>Houston</li>
<li>Lille</li>
<li>Madrid</li>
</settlement>
</list>
<tree>
<country name="Pays-Bas">
<noRegion>
<name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
</noRegion>
<name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
<name sortKey="Leentjens, Albert F G" sort="Leentjens, Albert F G" uniqKey="Leentjens A" first="Albert F. G." last="Leentjens">Albert F. G. Leentjens</name>
</country>
<country name="France">
<region name="Hauts-de-France">
<name sortKey="Dujardin, Kathy" sort="Dujardin, Kathy" uniqKey="Dujardin K" first="Kathy" last="Dujardin">Kathy Dujardin</name>
</region>
</country>
<country name="États-Unis">
<region name="Maryland">
<name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
</region>
<name sortKey="Marsh, Laura" sort="Marsh, Laura" uniqKey="Marsh L" first="Laura" last="Marsh">Laura Marsh</name>
<name sortKey="Richard, Irene H" sort="Richard, Irene H" uniqKey="Richard I" first="Irene H." last="Richard">Irene H. Richard</name>
</country>
<country name="Espagne">
<region name="Communauté de Madrid">
<name sortKey="Martinez Artin, Pablo" sort="Martinez Artin, Pablo" uniqKey="Martinez Artin P" first="Pablo" last="Martinez-Martin">Pablo Martinez-Martin</name>
</region>
</country>
<country name="Australie">
<noRegion>
<name sortKey="Starkstein, Sergio E" sort="Starkstein, Sergio E" uniqKey="Starkstein S" first="Sergio E." last="Starkstein">Sergio E. Starkstein</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006322 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006322 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:BAC9A14C486FC4DDDE842C685558E2300E5FB8FB
   |texte=   Symptomatology and markers of anxiety disorders in Parkinson's disease: A cross‐sectional study
}}

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024